Results 21 to 30 of about 163,730 (308)
OncoImmunology, 2013 These are exciting times for the field of cancer immunotherapy. Although the clinical efficacy of monoclonal antibodies has been demonstrated since the early 1990s, the therapeutic profile of other immunotherapeutic approaches-especially vaccines-has not yet been formally clarified.
Yaddanapudi, Kavitha +2 more
openaire +2 more sources
Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
Cell Reports, 2021 Summary: SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier and caused widespread disease in the past two decades. The development of a universal human coronavirus vaccine could prevent future pandemics.
Madeleine F. Jennewein +28 more
doaj +1 more source
The Cancer Journal, 2011 To date, in lung cancer, early attempts to modulate the immune system via vaccine-based therapeutics have been unsuccessful. An improved understanding of tumor immunology has facilitated the production of more sophisticated lung cancer vaccines. It is anticipated that it will likely require multiple epitopes of a diverse set of genes restricted to ...
Ronan J, Kelly, Giuseppe, Giaccone
openaire +2 more sources
Immunotherapy of lung cancer: An update [PDF]
, 2006 In Germany lung cancer is the leading cause of cancer-associated death in men. Surgery, chemotherapy and radiation may enhance survival of patients suffering from lung cancer but the enhancement is typically transient and mostly absent with advanced ...
Hatz, R. A. +15 more
core +1 more source
Cancer Vaccines in the Immunotherapy Era: Promise and Potential
, 2023 Therapeutic vaccines are a promising alternative for active immunotherapy for different types of cancers. Therapeutic cancer vaccines aim to prevent immune system responses that are not targeted at the tumors only, but also boost the anti-tumor immunity ...
Chaitenya Verma +6 more
core +1 more source
Aging and Cancer Vaccines [PDF]
Critical Reviews in Oncogenesis, 2013 Cancer vaccination is less effective at old than at young age, due to T cell unresponsiveness. This is caused by age-related changes of the immune system. Major immune defects at older age are lack of naive T cells, impaired activation pathways of T cells and antigen-presenting cells (APC), and age-related changes in the tumor microenvironment (TME ...
Claudia, Gravekamp, Dinesh, Chandra
openaire +2 more sources
Engineering New Approaches to Cancer Vaccines [PDF]
, 2015 available in PMC 2016 August 01Recently, a number of promising approaches have been developed using synthetic chemistry, materials science, and bioengineering-based strategies to address challenges in the design of more effective cancer vaccines.
Irvine, D. J. +2 more
core +1 more source
Human Papillomavirus Vaccines: An Updated Review
, 2020 Human papillomavirus (HPV) vaccines, which were introduced in many countries in the past decade, have shown promising results in decreasing HPV infection and related diseases, such as warts and precancerous lesions. In this review, we present the updated
Cheng, L, +5 more
core +1 more source
Oncolytic Vaccinia Virus in Lung Cancer Vaccines
, 2022 Therapeutic cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adverse effects by specifically targeting tumor-associated antigens. Oncolytic virus, especially vaccinia virus (VV) is
Cao-Sang Truong, So Young Yoo
core +1 more source